Marchantin A-treated MCF-7 cells show suppressed cyclin B1 gene expression, whereas marchantin C-treated human A172 glioma cells show increased cyclin B1 levels, indicating the different methods of cell cycle regulations of the two compounds [128]. The gene discussed is CCNB1; the disease is central nervous system cancer.